Avisi Technologies
Avisi Technologies is a clinical-stage medical device company dedicated to advancing vision care through innovative ophthalmic solutions. They are developing state-of-the-art treatments for glaucoma and other ocular conditions, including their flagship VisiPlate® aqueous shunt, a sustained drug delivery platform, and a device to treat mild glaucoma. Their mission is to restore health and promote vitality by creating accessible and cutting-edge healthcare solutions, with a focus on minimally-invasive treatments and nanotechnology-enabled devices.
Industries
Nr. of Employees
small (1-50)
Avisi Technologies
1733 Woodside Rd, Suite 310, Redwood City, CA 94061
Patents
Products
Ultrathin multichannel aqueous shunt (investigational)
An investigational ultrathin implant composed of metamaterial layers with interconnected microchannels designed to wick and drain aqueous humor to a secondary drainage zone to lower intraocular pressure.
Sustained ocular drug delivery platform (investigational)
A platform under development intended to enable sustained intraocular drug delivery to complement implantable glaucoma treatments.
Device for treatment of mild glaucoma (investigational)
A pipeline device concept intended to address mild forms of glaucoma as part of the development portfolio.
Ultrathin multichannel aqueous shunt (investigational)
An investigational ultrathin implant composed of metamaterial layers with interconnected microchannels designed to wick and drain aqueous humor to a secondary drainage zone to lower intraocular pressure.
Sustained ocular drug delivery platform (investigational)
A platform under development intended to enable sustained intraocular drug delivery to complement implantable glaucoma treatments.
Device for treatment of mild glaucoma (investigational)
A pipeline device concept intended to address mild forms of glaucoma as part of the development portfolio.
Expertise Areas
- Clinical trial management for early‑stage devices
- Ophthalmic implant research and development
- Microfabrication and MEMS-based manufacturing
- Biomaterials for implantable devices and anti‑fibrotic strategies
Key Technologies
- Nanofabrication and metamaterials for implants
- MEMS microfabrication
- Medical‑grade polymer and inorganic thin‑film combinations for implants
- Multichannel microfluidic network design
News & Updates
Avisi Technologies announced encouraging six-month interim results from the VITA trial evaluating its VisiPlate® device, an ultrathin, multichannel aqueous shunt in study subjects diagnosed with open-angle glaucoma. Data were presented by Dr. Eydie Miller-Ellis at the American Glaucoma Society Annual Meeting.
A report on the positive six-month results for VisiPlate® from the VITA trial presented by Dr. Eydie Miller-Ellis at the American Glaucoma Society, highlighting the device's safety and effectiveness.
Avisi Technologies' CEO Rui Jing Jiang participated in panel discussions on leadership and design strategies at the 2025 MedTech Summit, emphasizing success in the MedTech industry.
Avisi Technologies announced encouraging six-month interim results from the VITA trial evaluating its VisiPlate® device, an ultrathin, multichannel aqueous shunt in study subjects diagnosed with open-angle glaucoma. Data were presented by Dr. Eydie Miller-Ellis at the American Glaucoma Society Annual Meeting.
A report on the positive six-month results for VisiPlate® from the VITA trial presented by Dr. Eydie Miller-Ellis at the American Glaucoma Society, highlighting the device's safety and effectiveness.
Avisi Technologies' CEO Rui Jing Jiang participated in panel discussions on leadership and design strategies at the 2025 MedTech Summit, emphasizing success in the MedTech industry.